Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects with Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies.
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ul...